Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome

Circulating Factor Associated with Increased Glomerular Permeability to Albumin in Recurrent Focal Segmental Glomerulosclerosis

Virginia J. Savin, Ram Sharma, Mukut Sharma et al. · New England Journal of Medicine · 1996 · 711 citations · Full text

Medicine, Nephrology, Pathology +14

Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down‐regulation of the T cell costimulatory molecule CD40 ligand: An open‐label trial

Petros P. Sfikakis, John Boletis, Sophia Lionaki et al. · Arthritis & Rheumatism · 2005 · 413 citations

Life Sciences, Immunology, Pharmacotherapy +17

Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients

Nöel Milpied, B. Vasseur, Nathalie Parquet et al. · Annals of Oncology · 2000 · 376 citations · Full text

Life Sciences, Hematology, Immunology +16

European Best Practice Guidelines for Renal Transplantation (Part 2).

F. Berthoux, Daniel Abramovicz, Henrik Ekberg et al. · Lund University Publications (Lund University) · 2002 · 372 citations

Medicine, Nephrology, Surgery +16

REDUCTION IN IMMUNOSUPPRESSION AS INITIAL THERAPY FOR POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER: ANALYSIS OF PROGNOSTIC VARIABLES AND LONG-TERM FOLLOW-UP OF 42 ADULT PATIENTS1

Donald E. Tsai, Christine Hardy, John E. Tomaszewski et al. · Transplantation · 2001 · 364 citations

Medicine, Immunology, Surgery +16